Scientific board

The Scientific Board is composed of recognized experts who support research on medical cannabis.

Acting in a neutral and independent manner, they explore new therapeutic indications based on information directly  collected from patients and the medical profession.

In addition to providing objective scientific information to the public, they share the results of their research with the Swiss regulatory authorities in order to positively influence the legal framework.

claude vaney cannabis médical.jpeg
Screen Shot 2021-08-26 at 15.41.01.png

Dr. Claude Vaney, Chief of Neurorehabilitation Specialist in Neurology FMH.
President of the Swiss Society of Cannabis in Medicine.

Over the past few years, Claude Vaney has developed neurorehabilitation at the Bernese Montana Clinic and has developed it as a whole, particularly in the field of patients with multiple sclerosis and after a stroke.
Since then, he has dedicated himself to the medicalization of cannabis in his work as a practitioner at the Meyriez Hospital, as vice-president of the Swiss Multiple Sclerosis Society and as a member of the Parkinson.ch committee.
Since then, he dedicates his activity as a practitioner at the Meyriez hospital, as vice-president of the Swiss Multiple Sclerosis Society and within the committee of Parkinson.ch to the medicalization of cannabis.

olivier menzel.jpeg
Screen Shot 2021-08-26 at 15.41.01.png

Olivier Menzel, PhD in molecular and cellular biology, MBA.

His passion for genetics has motivated his choice to dedicate his life to human genetic diseases.
He spent more than 15 years in laboratories working on scientific research projects on rare diseases. 
At the same time, he created the BLACKSWAN Foundation, an internationally renowned non-profit foundation to support research on orphan diseases.
Member of several scientific committees, "patient expert" (PPI - Patients & Public Involvement) he fights for the recognition and involvement of patients in health and research, and is a strong advocate of personalized medicine.
He is responsible for the strategic partnerships and business development of the Health 2030 Genome Center, a national genomics center.

davide staedler.jpeg
Screen Shot 2021-08-26 at 15.41.01.png

Davide Staedler, Dr ès sc. EPF; 

Privat Docent, Dip. di Scienze Biomediche, UNIL

Graduated from the University of Lausanne (Faculty of Biology and Medicine, 2010) with in medical biology and pharmacology, he holds a PhD in medicinal chemistry from the EPFL (2014).
Davide Staedler follows both an academic and a private sector career path. Since 2009 he has been managing the company TIBIO, specialized in scientific consulting in chemistry and biotechnology, which he founded during his studies in biology.
In parallel, from 2015 to 2021 he was Scientific Director of Scitec Research, one of the most important laboratories in Switzerland. Passionate about industrial applications, he is a member of the Board of Directors of several start-ups in the field of Life Sciences.
At the same time, he is also a Privat Docent in Pharmacology and Toxicology at the Department of Biomedical Sciences of the University of Lausanne as well as a lecturer at the School of Biology of the same university, where he teaches entrepreneurship applied to biology and industrial biotechnology.

Screen Shot 2021-08-26 at 15.41.01.png
simon reboh.png

Simon Reboh, PhD, TCM MD – Nutritional Neuroscientist & Clinical Pharmacist, UNIL

Pharmacist graduated from the University of Lausanne (Faculty of Sciencespharmaceuticals), and graduated from the Faculty of Beijing, PhD TCM and Ms in Qi Gong, he holds a doctorate in Chinese medicine and is certified in nutrigenomics from the University of Burgundy.
Simon Reboh is a practitioner 
recognized in integrative health which develops approaches in multidisciplinary regenerative medicine.
Based on more than 12 years of practice in clinical research, he explores the European and Asian pharmacopoeia and is passionate aboutdevelopment of protocols related to cell regeneration.
Alongside numerous collaborations with several research centersEPFL research (epigenetics, nanotechnology, prevention ofrisk factors, genetic sequencing), he directs the SISLAB laboratory (specialized in the personalization of treatment) and the Sen’Su pharmacy (12 employees) where he works as a clinician with health professionals (internists, oncologists) for the implementation of personalized treatment protocols.
Entrepreneur and speaker in the field of health, he is involved in theresearch in association with EPFL in the field of epigenetics.